Amicus Therapeutics, Inc. (FOLD) Q3 2009 Earnings Results

Amicus Therapeutics Beats on EPS, Stock Up 0.72%

Amicus Therapeutics reported a strong EPS performance, significantly exceeding expectations. The stock reacted positively, rising 0.72% following the announcement. The lack of revenue figures and guidance leaves some uncertainty, but the strong EPS suggests effective cost management or operational efficiencies.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$0.51	N/A	+171.83%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Management expressed satisfaction with the EPS results, highlighting their commitment to pipeline development. However, they did not provide specific guidance for future performance.

We are pleased with our EPS performance this quarter.

Our focus remains on advancing our pipeline.

Amicus Therapeutics Beats on EPS, Stock Up 0.72%

Key numbers

Management commentary

Amicus Therapeutics, Inc.

More earnings this week

Amicus Therapeutics Beats on EPS, Stock Up 0.72%

Key numbers

Management commentary